mardi 12 janvier 2016

Onco Actu du 12 janvier 2016

1. Biologie

Researchers uncover weakness in leukaemia cells [Cancer Research UK]

2. Etiologie

Cancer--luck or environment? Part II: Nothing to food-fight over [The Mermaid's Tale]

Food-Fight Alert!! Is cancer bad luck or environment? Part I: the basic issues [The Mermaid's Tale]

Why most cancer isn’t attributable to simple ‘bad luck’ [The Guardian]

3.3 Prévention - Vaccins

We know it's effective. So why is there opposition to the HPV vaccine ? [The Guardian]

4. Dépistage, diagnostic et pronostic

Cancer Diagnostics 2020: Emerging Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Supplier Shares, Country Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review [ReportsnReports]

4.12 Biopsies liquides

Genomic Health Announces Plans to Launch Liquid Biopsy Mutation Panel in 2016 [Genomic Health]

4.9 Dép., diag. & prono. - Sein

New breast cancer screening guidelines at odds with Congress [Washington Post]

Federal Panel Finalizes Mammogram Advice That Stirred Controversy [NPR]

American Cancer Society Responds to USPSTF Breast Cancer Screening [ACS]

A Turning Point In The Breast Cancer Screening Debate? [Forbes]

Better treatment for breast cancer hasn't boosted the benefit of mammograms, study says [LA Times]

Panel Reasserts Mammogram Advice That Triggered Breast Cancer Debate [NY Times]

U.S. panel finalizes breast cancer screening recommendations [Reuters]

5. Traitements

Arthritis drug could also help combat ovarian cancer [NHS Choices]

Early-Stage Prostate Cancer: To Treat or Not to Treat [CANCER RESEARCH Catalyst]

5.12 Immunothérapies

Cellectis Announces a New CAR Architecture Controlling CAR T-Cell Functions [Cellectis]

Turning your cancer against itself [STAT]

Juno Acquires Harvard Spinout, AbVitro, For $125M To Discover More Cancer Immunotherapies [Forbes]

5.12.1 Immunothérapies - partenariats

Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology [Novartis]

Rival drug firms team up to test new cancer treatment approach [STAT]

Drug Companies to Try a Unified Front Against Cancer [NY Times]

Novartis signs $170 million immuno-oncology pact with Surface [Reuters]

5.2 Pharma

Exelixis Submits Marketing Authorization Application in the European Union for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma [Exelixis]

5.2.1 Pharma - Partenariats

AstraZeneca and Incyte announce new lung cancer clinical trial collaboration [AstraZeneca]

AstraZeneca and MedImmune in oncology research deals [Pharmafile]

5.2.2 Pharma - Fusions & Acquisitions

Merck buys out IOmet, adding new immuno-oncology tech [FierceBiotech]

Drugmaker Shire to buy Baxalta for $32 billion after six-month pursuit [Reuters]

5.5 ASCO

Some Hodgkin Lymphoma Survivors May Not Receive All Recommended Follow-Up [ASCO]

Personalized Survivorship Care Plans Improve Health Outcomes for Low-Income Breast Cancer Survivors [ASCO]

Persistent Chemotherapy-Induced Peripheral Neuropathy (CIPN) Is Common in Female Cancer Survivors, Altering Gait and Increasing Falls [ASCO]

6.1 Observation

Should the NHS publish data on cancer surgeons? [Cancer Research UK]

Why are women with brain tumours being dismissed as attention-seekers? [The Guardian]

6.10 Politiques

NIH asked to fight price gouging by overriding drug patents [STAT]

6.6 Publications

Cancer Cell paper under investigation following anonymous queries on PubPeer [Retraction Watch]